Beacon Pharmaceuticals Ltd.
Additional OffersShow all
Ibrutinib, is a kinase inhibitor indicated for the treatment of patients with: • Mantle cell lymphoma (MCL), who have received at least one prior ther... View More
Administer once daily at approximately the same time each day. Capsules should be taken orally with a glass of water. The capsules should not be opened,... View More
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia 420 mg taken orally once daily (three 140 mg capsules once daily... View More
Safety and efficacy not established
Hypersensitivity. Concomitant use w/ St. John's wort-containing prep.
Mode of Action
Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of... View More
• Hemorrhage: Should be monitored for bleeding • Infections: Patients should be monitored for fever and infections and evaluated promptly • Cytopen... View More
>10% (MCL) Increased serum creatinine, 1.5 x ULN (67%) Platelets decreased, all grades (57%) Diarrhea (51%) Hemorrhage (48%) Neutrophils decreased,... View More
Increased exposure w/ medicinal products that strongly or moderately inhibit CYP3A4. Avoid grapefruit & Seville oranges as these contain moderate inhibi... View More
Alternative brand for Ibrutix 140
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not... View More